Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | PGR | P06401 | 2/20 | 0.59 |
| ▸ | ESRRG | P62508 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | GBA1 | P04062 | 1/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.59 |
| ▸ | PRKCG | P05129 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | PRKCB | P05771 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL227233 | 1.00 | ESR1 (0.59) | ESR1ESR2MAPTCYP3A4MEN1 | |
| SCHEMBL3773026 | 0.95 | ESR1 (0.65) | ESR1ESR2MAPTCYP3A4MEN1 | |
| SCHEMBL10506418 | 0.95 | ESR1 (0.65) | ESR1ESR2MAPTCYP3A4MEN1 | |
| SCHEMBL10506428 | 0.95 | ESR1 (0.65) | ESR1ESR2MAPTCYP3A4MEN1 | |
| SCHEMBL30289809 | 0.87 | ESR1 (0.52) | ESR1ESR2MAPTCYP3A4MEN1 | |
| Citric Acid SCHEMBL10954226 | 0.86 | ESR1 (0.68) | ESR1ESR2MAPTCYP3A4MEN1 | |
| SCHEMBL30677997 | 0.86 | ESR1 (0.61) | ESR1ESR2MAPTCYP3A4MEN1 | |
| SCHEMBL10828019 | 0.84 | ESR1 (0.54) | ESR1ESR2MAPTCYP3A4MEN1 | |
| SCHEMBL7547707 | 0.84 | ESR1 (0.60) | ESR1ESR2MAPTCYP3A4MEN1 | |
| SCHEMBL7547715 | 0.84 | ESR1 (0.60) | ESR1ESR2MAPTCYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5945456-A | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells | NEORX CORPORATION (US) | 1999-08-31 | — | — | US | claimed |
| US-5847007-A | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells | NEORX CORPORATION (US) | 1998-12-08 | — | — | US | claimed |
| US-5773479-A | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells | NEORX CORPORATION (US) | 1998-06-30 | — | — | US | claimed |
| US-20190016812-A1 | NOVEL ANTI-TNFSF9 ANTIBODIES AND METHODS OF USE | ABBVIE STEMCENTRX LLC (US) | 2019-01-17 | — | — | US | disclosed |
| US-20170239365-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| US-9376440-B2 | Pyrrolobenzodiazepines as antiproliferative agents | MEDIMMUNE LIMITED (GB) | 2016-06-28 | — | — | US | disclosed |
| US-20150133435-A1 | PYRROLOBENZODIAZEPINES | MEDIMMUNE LIMITED (GB) | 2015-05-14 | — | — | US | disclosed |
| EP-2205242-B1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH INC (US) | 2015-04-15 | — | — | EP | disclosed |
| WO-2011072244-A1 | METHOD OF TREATMENT OF BREAST CANCER WITH TAMOXIFEN | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2011-06-16 | — | — | WO | disclosed |
| US-5945456-A | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells | NEORX CORPORATION (US) | 1999-08-31 | — | — | US | disclosed |
| US-5847007-A | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells | NEORX CORPORATION (US) | 1998-12-08 | — | — | US | disclosed |
| US-5811447-A | Therapeutic inhibitor of vascular smooth muscle cells | NEORX CORPORATION (US) | 1998-09-22 | — | — | US | disclosed |
| US-5773479-A | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells | NEORX CORPORATION (US) | 1998-06-30 | — | — | US | disclosed |
| US-5770609-A | ADMINISTERING TAMOXIFEN DERIVATIVES TO INHIBIT SMOOTH MUSCLE CELL PROLIFERATION ASSOCIATED WITH VASCULAR TRAUMA FROM SURGERY OR TRANSPLANTATION OF ORGANS OR MEDICAL DEVICES | NEORX CORPORATION (US) | 1998-06-23 | — | — | US | disclosed |
| US-5733925-A | ADMINISTERING TAXOL TREATING CARDIOVASCULAR DISORDER | NEORX CORPORATION (US) | 1998-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239365-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, BOD1L1, GABRA1 | ESR1 4258/4885ESR2 4165/4885MAPT 3731/4885 |
| US-20150133435-A1 | PYRROLOBENZODIAZEPINES | MBD2, DDB1, PDCD1 | ESR1 3561/4885ESR2 2695/4885MAPT 61/4885 |
| US-20190016812-A1 | NOVEL ANTI-TNFSF9 ANTIBODIES AND METHODS OF USE | TNFRSF9, TNFRSF1A, TNFSF11 | ESR1 3828/4885ESR2 3243/4885MAPT 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.